AXNX - Axonics Modulation Technologies Inc Stock Price, Fair Value and News

67.32USD+0.02 (+0.03%)Delayed as of 17 Apr 2024, 01:59 pm ET

Market Summary

USD67.32+0.02

Delayedas of 17 Apr 2024, 01:59 pm

0.03%

AXNX Stock Price

View Fullscreen

AXNX RSI Chart

AXNX Valuation

Market Cap

3.4B

Price/Earnings (Trailing)

-565.58

Price/Sales (Trailing)

9.37

EV/EBITDA

872.96

Price/Free Cashflow

-616.7

AXNX Price/Sales (Trailing)

AXNX Profitability

EBT Margin

-2.39%

Return on Equity

-0.95%

Return on Assets

-0.84%

Free Cashflow Yield

-0.16%

AXNX Fundamentals

AXNX Revenue

Revenue (TTM)

366.4M

Rev. Growth (Yr)

27.72%

Rev. Growth (Qtr)

17.87%

AXNX Earnings

Earnings (TTM)

-6.1M

Earnings Growth (Yr)

891.43%

Earnings Growth (Qtr)

67.85%

Breaking Down AXNX Revenue

52 Week Range

47.5967.36

(Low)(High)

Last 7 days

-0.7%

Last 30 days

-0.7%

Last 90 days

-1.5%

Trailing 12 Months

15.4%

How does AXNX drawdown profile look like?

AXNX Financial Health

Current Ratio

10.73

Debt/Equity

1e-4

Debt/Cashflow

-22.65

AXNX Investor Care

Shares Dilution (1Y)

2.08%

Diluted EPS (TTM)

-0.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	295.9M	319.8M	342.6M	366.4M
2022	194.3M	217.4M	240.9M	273.7M
2021	119.6M	150.3M	161.9M	180.3M
2020	39.0M	52.8M	86.7M	111.5M
2019	2.0M	3.3M	4.4M	13.8M
2018	0	369.7K	538.3K	707.0K
2017	0	0	0	201.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Axonics Modulation Technologies Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 31, 2024	keese kari leigh	sold	-236,331	67.7359	-3,489	chief financial officer
Jan 31, 2024	woock john	sold	-1,076,930	67.7359	-15,899	evp, chief mktg/strtgy officer
Jan 31, 2024	cohen raymond w	sold	-2,381,660	67.7359	-35,161	chief executive officer
Jan 31, 2024	ford alfred j jr	acquired	-	-	25,500	chief commercial officer
Jan 31, 2024	noblett karen	sold	-764,603	67.7359	-11,288	chief medical officer
Jan 31, 2024	sama rinda	acquired	-	-	28,000	chief operating officer
Jan 31, 2024	keese kari leigh	acquired	-	-	6,167	chief financial officer
Jan 31, 2024	noblett karen	acquired	-	-	27,500	chief medical officer
Jan 31, 2024	woock john	acquired	-	-	28,000	evp, chief mktg/strtgy officer
Jan 31, 2024	ford alfred j jr	sold	-1,125,430	67.7359	-16,615	chief commercial officer

Which funds bought or sold AXNX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	Legato Capital Management LLC	sold off	-100	-628,834	-	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-22.59	-5,948	35,933	-%
Apr 12, 2024	INSPIRION WEALTH ADVISORS, LLC	new	-	206,910	206,910	0.03%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	new	-	1,104	1,104	-%
Apr 11, 2024	FORT PITT CAPITAL GROUP, LLC	new	-	344,850	344,850	0.01%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	unchanged	-	88.00	897	-%
Apr 05, 2024	NBC SECURITIES, INC.	reduced	-0.15	5,000	46,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	75.00	633	1,448	-%
Apr 05, 2024	CWM, LLC	reduced	-0.5	1,000	14,000	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	new	-	285,467	285,467	-%

Are Funds Buying or Selling AXNX?

Are funds buying AXNX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AXNX

No. of Funds

Unveiling Axonics Modulation Technologies Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	10.38%	5,260,830	SC 13G/A
Feb 12, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 25, 2024	blackrock inc.	8.3%	4,189,817	SC 13G/A
Dec 11, 2023	fmr llc	-	0	SC 13G/A
Mar 10, 2023	vanguard group inc	10.28%	5,092,888	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.82%	4,863,283	SC 13G/A
Jan 31, 2023	blackrock inc.	7.3%	3,630,843	SC 13G/A
Jun 06, 2022	cooperatieve gilde healthcare iv u.a.	0%	0	SC 13G/A

Recent SEC filings of Axonics Modulation Technologies Inc

View All Filings

Date Filed	Form Type	Document
Apr 04, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 07, 2024	DEFA14A	DEFA14A
Feb 29, 2024	10-K	Annual Report
Feb 28, 2024	8-K	Current Report
Feb 22, 2024	DEFM14A	DEFM14A
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 12, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report
Feb 07, 2024	PREM14A	PREM14A

Peers (Alternatives to Axonics Modulation Technologies Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	189.6B	40.1B	-5.40%	4.53%	33.12	4.73	-8.12%	-17.45%
BDX	66.7B	19.5B	-2.42%	-9.87%	53.13	3.42	4.02%	-22.04%
ALGN	22.9B	3.9B	-2.94%	-12.25%	51.49	5.93	3.42%	23.09%
BAX	20.1B	14.8B	-4.93%	-7.94%	7.56	1.36	2.12%	209.17%
MID-CAP
HSIC	9.2B	12.3B	-4.49%	-14.03%	22	0.74	-2.44%	-22.68%
ATR	9.2B	3.5B	-1.69%	15.70%	32.17	2.62	4.97%	18.89%
BIO	8.5B	2.7B	-12.27%	-39.23%	-13.41	3.2	-4.68%	82.43%
XRAY	6.4B	4.0B	-6.21%	-24.72%	-47.49	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-0.75%	15.36%	-565.58	9.37	33.86%	89.83%
PDCO	2.3B	6.6B	-5.91%	-4.69%	11.86	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.61%	-18.37%	-1.88	0.4	7.73%	-1066.14%
ANIK	380.0M	166.7M	0.59%	-11.05%	-4.6	2.28	6.67%	-456.34%
ANGO	260.4M	324.0M	21.04%	-28.41%	-1.35	0.8	-3.19%	-337.41%
APYX	48.2M	52.3M	-22.35%	-53.67%	-2.57	0.92	17.61%	19.28%
AEMD	3.8M	3.7M	-16.76%	269.23%	-0.31	1.01	5.77%	8.23%

Axonics Modulation Technologies Inc News

Latest updates

Axonics Modulation Technologies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	17.9%	109,735,000	93,100,000	92,894,000	70,650,000	85,918,000	70,384,000	68,980,000	48,420,000	53,135,000	46,913,000	45,869,000	34,373,000	34,783,000	35,243,000	15,213,000	26,296,000	9,946,000	1,309,000	1,488,000	1,077,000	494,000
Gross Profit	19.8%	82,760,000	69,104,000	70,190,000	52,500,000	62,967,000	51,260,000	50,196,000	33,242,000	35,391,000	31,194,000	28,734,000	20,399,000	22,131,000	21,809,000	6,750,000	16,401,000	5,408,000	677,000	716,000	529,000	249,000
Operating Expenses	17.1%	81,694,000	69,791,000	82,260,000	66,866,000	66,576,000	67,635,000	71,625,000	56,775,000	53,071,000	47,696,000	44,744,000	42,015,000	33,012,000	30,578,000	26,155,000	31,106,000	28,071,000	25,724,000	19,986,000	14,148,000	9,700,000
S&GA Expenses	15.9%	55,094,000	47,544,000	44,270,000	42,654,000	43,824,000	39,751,000	39,381,000	33,063,000	31,338,000	28,112,000	25,411,000	20,928,000	18,284,000	17,057,000	14,220,000	16,569,000	16,301,000	15,707,000	10,750,000	5,914,000	1,416,000
R&D Expenses	18.9%	9,714,000	8,167,000	8,949,000	8,056,000	8,103,000	7,936,000	7,135,000	11,236,000	10,182,000	8,648,000	9,098,000	9,369,000	8,111,000	7,719,000	6,370,000	6,855,000	6,118,000	4,855,000	4,874,000	4,219,000	4,783,000
EBITDA Margin	295.1%	0.01	-0.01	-0.07	-0.13	-0.18	-0.28	-0.32	-0.34	-0.38	-0.39	-0.39	-0.50	-	-	-	-	-	-	-	-	-
Interest Expenses	-12.5%	14,000	16,000	39,000	-	-	-	-	1,000	-	1,000	2,007,000	170,000	253,000	256,000	264,000	329,000	339,000	367,000	370,000	360,000	358,000
Income Taxes	-161.8%	-1,118,000	-427,000	-304,000	-807,000	-522,000	-520,000	-465,000	-1,111,000	-2,487,000	528,000	3,296,000	-555,000	-	-	-	1,000	-	-	1,000	-	-
Earnings Before Taxes	55.8%	5,456,000	3,501,000	-7,646,000	-10,055,000	143,000	-16,772,000	-21,908,000	-23,779,000	-17,653,000	-16,722,000	-21,852,000	-23,058,000	-11,348,000	-9,168,000	-19,783,000	-14,615,000	-22,751,000	-25,006,000	-19,060,000	-13,117,000	-9,665,000
EBT Margin	41.8%	-0.02	-0.04	-0.11	-0.16	-0.23	-0.33	-0.37	-0.41	-0.44	-0.45	-0.44	-0.53	-	-	-	-	-	-	-	-	-
Net Income	67.8%	6,593,000	3,928,000	-7,342,000	-9,248,000	665,000	-16,252,000	-21,443,000	-22,668,000	-15,166,500	-17,250,000	-25,148,000	-22,503,000	-11,348,000	-9,168,000	-19,783,000	-14,616,000	-22,751,000	-25,006,000	-19,061,000	-13,117,000	-9,665,000
Net Income Margin	52.7%	-0.02	-0.04	-0.10	-0.16	-0.22	-0.31	-0.35	-0.41	-0.44	-0.47	-0.45	-0.53	-	-	-	-	-	-	-	-	-
Free Cashflow	-61.2%	4,323,000	11,151,000	-19,465,000	-1,575,000	9,018,000	2,884,000	-1,476,000	-9,458,000	-7,860,000	-3,678,000	-12,323,000	-25,706,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	9.0%	720	661	649	666	659	632	514	526	548	561	566	445	342	348	349	217	220	126	146	159	172
Current Assets	3.4%	491	475	455	470	465	449	313	307	321	330	332	228	328	334	336	204	212	118	138	153	165
Cash Equivalents	-28.9%	105	147	145	240	239	241	203	213	221	229	231	131	241	269	288	160	171	76.00	83.00	89.00	98.00
Inventory	6.7%	80.00	75.00	70.00	66.00	56.00	58.00	58.00	62.00	65.00	70.00	70.00	71.00	63.00	44.00	30.00	19.00	16.00	13.00	8.00	5.00	4.00
Net PPE	-100.0%	-	7.00	6.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00	6.00	6.00	6.00	6.00	6.00	5.00	3.00	3.00	3.00	3.00	3.00
Goodwill	4.3%	99.00	95.00	99.00	97.00	94.00	87.00	95.00	103	106	110	107	87.00	-	-	-	-	-	-	-	-	-
Liabilities	64.3%	82.00	50.00	48.00	89.00	89.00	83.00	76.00	62.00	66.00	71.00	61.00	115	55.00	54.00	51.00	45.00	37.00	34.00	32.00	28.00	29.00
Current Liabilities	28.7%	46.00	36.00	32.00	66.00	65.00	61.00	30.00	26.00	27.00	28.00	24.00	24.00	46.00	39.00	31.00	20.00	12.00	16.00	11.00	7.00	6.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	0.00	75.00	-	6.00	11.00	16.00	20.00	14.00	16.00	18.00	19.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	21.00	15.00	10.00	5.00	-	6.00	4.00	2.00	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	0.00	75.00	-	6.00	11.00	16.00	20.00	14.00	16.00	18.00	19.00
Shareholder's Equity	4.4%	638	611	601	577	570	550	438	463	482	490	504	330	287	294	298	172	183	92.00	114	131	143
Retained Earnings	1.7%	-380	-386	-390	-383	-374	-374	-358	-337	-314	-299	-282	-257	-234	-223	-213	-194	-179	-156	-131	-112	-99.65
Additional Paid-In Capital	1.1%	1,034	1,022	1,010	982	970	961	821	812	804	796	788	590	522	518	513	367	363	250	247	245	243
Shares Outstanding	0.2%	51.00	51.00	50.00	50.00	50.00	46.00	45.00	45.00	43.00	45.00	41.00	40.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	2,500	-	-	-	2,647	-	-	-	2,893	-	-	-	1,136	-	-	-	633	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-54.4%	5,630	12,344	-19,209	-781	9,353	3,847	-842	-9,167	-6,776	-2,994	-11,953	-25,583	-28,314	-19,146	-12,975	-23,307	-28,136	-23,904	-18,359	-13,055	-9,296
Share Based Compensation	-2.8%	11,148	11,470	11,204	10,714	8,757	8,218	7,905	7,138	6,844	6,690	6,327	5,303	3,582	3,775	3,816	3,922	2,921	2,782	1,875	1,142	247
Cashflow From Investing	-243.1%	-37,922	-11,053	-68,623	694	-10,030	-99,401	-10,632	-291	-1,084	-684	-370	-140,864	-1,023	-648	-553	11,878	12,342	17,456	11,440	4,049	-48,115
Cashflow From Financing	-34.2%	578	878	-6,766	1,930	161	131,883	480	1,444	202	1,523	112,573	56,215	1,055	1,296	141,495	344	110,492	111	308	44.00	135,579

AXNX Income Statement

2023-12-31

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Net revenue	$ 366,379	$ 273,702	$ 180,290
Cost of goods sold	91,825	76,037	64,572
Gross profit	274,554	197,665	115,718
Operating expenses
Research and development	34,886	34,410	37,297
General and administrative	45,754	40,238	30,041
Sales and marketing	189,562	156,019	105,789
Amortization of intangible assets	9,064	9,383	7,241
Acquisition-related costs	5,898	22,561	7,158
Acquired in-process research & development	15,447	0	0
Total operating expenses	300,611	262,611	187,526
Loss from operations	(26,057)	(64,946)	(71,808)
Other income (expense)
Interest and other income	16,690	5,133	40
Loss on disposal of property and equipment	(1)	(69)	(91)
Interest and other income (expense)	624	(2,434)	(7,426)
Other income (expense), net	17,313	2,630	(7,477)
Loss before income tax (benefit) expense	(8,744)	(62,316)	(79,285)
Income tax (benefit) expense	(2,656)	(2,618)	782
Net loss	(6,088)	(59,698)	(80,067)
Foreign currency translation adjustment	9,280	(18,587)	(6,129)
Comprehensive income (loss)	$ 3,192	$ (78,285)	$ (86,196)
Net loss per share, basic (in USD per share)	$ (0.12)	$ (1.28)	$ (1.86)
Net loss per share, diluted (in USD per share)	$ (0.12)	$ (1.28)	$ (1.86)
Weighted-average shares used to compute basic net loss per share (in shares)	49,081,470	46,684,478	43,072,298
Weighted-average shares used to compute diluted net loss per share (in shares)	49,081,470	46,684,478	43,072,298

AXNX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 104,811	$ 238,846
Short-term investments	240,149	118,365
Accounts receivable, net of allowance for credit losses of $442 and $321 at December 31, 2023 and 2022, respectively	57,243	44,817
Inventory, net	79,940	55,765
Prepaid expenses and other current assets	9,279	7,282
Total current assets	491,422	465,075
Restricted cash	12,714	0
Property and equipment, net	10,760	6,798
Intangible assets, net	81,375	86,253
Other assets	24,235	6,813
Goodwill	99,417	94,414
Total assets	719,923	659,353
Current liabilities
Accounts payable	18,452	9,070
Accrued liabilities	10,527	6,520
Accrued compensation and benefits	15,060	15,495
Operating lease liabilities, current portion	1,777	1,562
Other current liabilities	0	32,600
Total current liabilities	45,816	65,247
Operating lease liabilities, net of current portion	25,840	7,555
Deferred tax liabilities, net	10,703	16,412
Total liabilities	82,359	89,214
Commitments and contingencies (Note 4)
Stockholders’ equity
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, par value $0.0001 per share, 75,000,000 shares authorized at December 31, 2023 and 2022; 50,770,520 and 49,546,727 shares issued and outstanding at December 31, 2023 and 2022, respectively	5	5
Additional paid-in capital	1,033,778	969,545
Accumulated deficit	(380,352)	(374,264)
Accumulated other comprehensive loss	(15,867)	(25,147)
Total stockholders’ equity	637,564	570,139
Total liabilities and stockholders’ equity	$ 719,923	$ 659,353

About Axonics Modulation Technologies Inc

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

CEO	Mr. Raymond W. Cohen
WEBSITE	axonics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	610

Axonics Modulation Technologies Inc Frequently Asked Questions

What is the ticker symbol for Axonics Modulation Technologies Inc? What does AXNX stand for in stocks?

AXNX is the stock ticker symbol of Axonics Modulation Technologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Axonics Modulation Technologies Inc (AXNX)?

As of Tue Apr 16 2024, market cap of Axonics Modulation Technologies Inc is 3.43 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXNX stock?

You can check AXNX's fair value in chart for subscribers.

What is the fair value of AXNX stock?

You can check AXNX's fair value in chart for subscribers. The fair value of Axonics Modulation Technologies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Axonics Modulation Technologies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Axonics Modulation Technologies Inc a good stock to buy?

The fair value guage provides a quick view whether AXNX is over valued or under valued. Whether Axonics Modulation Technologies Inc is cheap or expensive depends on the assumptions which impact Axonics Modulation Technologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXNX.

What is Axonics Modulation Technologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, AXNX's PE ratio (Price to Earnings) is -565.58 and Price to Sales (PS) ratio is 9.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXNX PE ratio will change depending on the future growth rate expectations of investors.